- Home
- CMMB vs RANI Comparison
CMMB vs RANI Comparison
Compare CMMB & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- RANI
- Stock Information
- Founded
- CMMB 2004
- RANI 2012
- Country
- CMMB Israel
- RANI United States
- Employees
- CMMB N/A
- RANI N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- RANI Medicinal Chemicals and Botanical Products
- Sector
- CMMB Health Care
- RANI Health Care
- Exchange
- CMMB Nasdaq
- RANI Nasdaq
- Market Cap
- CMMB 23.0M
- RANI 19.6M
- IPO Year
- CMMB N/A
- RANI 2021
- Fundamental
- Price
- CMMB $1.19
- RANI $0.52
- Analyst Decision
- CMMB Strong Buy
- RANI Strong Buy
- Analyst Count
- CMMB 2
- RANI 4
- Target Price
- CMMB $8.50
- RANI $7.75
- AVG Volume (30 Days)
- CMMB 211.9K
- RANI 287.3K
- Earning Date
- CMMB 08-20-2025
- RANI 08-05-2025
- Dividend Yield
- CMMB N/A
- RANI N/A
- EPS Growth
- CMMB N/A
- RANI N/A
- EPS
- CMMB N/A
- RANI N/A
- Revenue
- CMMB N/A
- RANI $1,200,000.00
- Revenue This Year
- CMMB N/A
- RANI N/A
- Revenue Next Year
- CMMB N/A
- RANI N/A
- P/E Ratio
- CMMB N/A
- RANI N/A
- Revenue Growth
- CMMB N/A
- RANI N/A
- 52 Week Low
- CMMB $0.87
- RANI $0.46
- 52 Week High
- CMMB $2.55
- RANI $4.20
- Technical
- Relative Strength Index (RSI)
- CMMB 40.31
- RANI 35.23
- Support Level
- CMMB $1.17
- RANI $0.51
- Resistance Level
- CMMB $1.24
- RANI $0.56
- Average True Range (ATR)
- CMMB 0.07
- RANI 0.03
- MACD
- CMMB -0.01
- RANI 0.01
- Stochastic Oscillator
- CMMB 34.67
- RANI 19.29
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.